Literature DB >> 28536278

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Laetitia Fend1,2, Takahiro Yamazaki2,3,4, Christelle Remy1, Catherine Fahrner1, Murielle Gantzer1, Virginie Nourtier1, Xavier Préville1,5, Eric Quéméneur1, Oliver Kepp6,7,8,9,10, Julien Adam2,11, Aurélien Marabelle12, Jonathan M Pitt2,3,4, Guido Kroemer6,7,8,9,10,13,14, Laurence Zitvogel15,3,4,11,16.   

Abstract

Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatment, the ability to induce immune-mediated regression of distant metastases is still poorly documented. We report here that the engineered oncolytic vaccinia virus VVWR-TK-RR--Fcu1 can induce immunogenic cell death and generate a systemic immune response. Effects on tumor growth and survival was largely driven by CD8+ T cells, and immune cell infiltrate in the tumor could be reprogrammed toward a higher ratio of effector T cells to regulatory CD4+ T cells. The key role of type 1 IFN pathway in oncolytic virotherapy was also highlighted, as we observed a strong abscopal response in Ifnar-/- tumors. In this model, single administration of virus directly into the tumors on one flank led to regression in the contralateral flank. Moreover, these effects were further enhanced when oncolytic treatment was combined with immunogenic chemotherapy or with immune checkpoint blockade. Taken together, our results suggest how to safely improve the efficacy of local oncolytic virotherapy in patients whose tumors are characterized by dysregulated IFNα signaling. Cancer Res; 77(15); 4146-57. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28536278     DOI: 10.1158/0008-5472.CAN-16-2165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

Review 2.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 3.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

4.  Tumor lysis with LTX-401 creates anticancer immunity.

Authors:  Wei Xie; Laura Mondragón; Brynjar Mauseth; Yan Wang; Jonathan Pol; Sarah Lévesque; Heng Zhou; Takahiro Yamazaki; Johannes J Eksteen; Laurence Zitvogel; Baldur Sveinbjørnsson; Øystein Rekdal; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-13       Impact factor: 8.110

5.  In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.

Authors:  Danny N Khalil; Nathan Suek; Luis Felipe Campesato; Sadna Budhu; David Redmond; Robert M Samstein; Chirag Krishna; Katherine S Panageas; Marinela Capanu; Sean Houghton; Daniel Hirschhorn; Roberta Zappasodi; Rachel Giese; Billel Gasmi; Michael Schneider; Aditi Gupta; James J Harding; John Alec Moral; Vinod P Balachandran; Jedd D Wolchok; Taha Merghoub
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

Review 6.  Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.

Authors:  Julie M Collins; Jason M Redman; James L Gulley
Journal:  Expert Rev Vaccines       Date:  2018-08-22       Impact factor: 5.217

7.  Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.

Authors:  Qizhen Cao; Wanqin Wang; Min Zhou; Qian Huang; Xiaoxia Wen; Jun Zhao; Sixiang Shi; Ku Geng; Fenge Li; Hiroto Hatakeyama; Chunyu Xu; David Piwnica-Worms; Weiyi Peng; Dapeng Zhou; Anil K Sood; Chun Li
Journal:  Nanomedicine       Date:  2020-02-12       Impact factor: 5.307

Review 8.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

9.  Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.

Authors:  Yusuke Mochizuki; Hiroshi Tazawa; Koji Demiya; Miho Kure; Hiroya Kondo; Tadashi Komatsubara; Kazuhisa Sugiu; Joe Hasei; Aki Yoshida; Toshiyuki Kunisada; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968

Review 10.  Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities.

Authors:  Camille Jacqueline; Nathalie Bonnefoy; Guillaume M Charrière; Frédéric Thomas; Benjamin Roche
Journal:  Oncoimmunology       Date:  2018-06-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.